Moleculin Biotech, Inc. 10-Q

ITEM 5. OTHER INFORMATION.    During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).   21 Table of Contents   ITEM 6. EXHIBITS    Exhibit No.   Description       10.1*   First Amendment to Commercial Lease Agreement for 5300 Memorial       31.1*   Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002       31.2*   Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002       32.1*+   Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002       32.2*+   Certification of Principal Accounting and Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002       101.INS*   Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)        101.SCH*   Inline XBRL Taxonomy Extension Schema Document       101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document       101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document       101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document       101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document       104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)   * Filed herewith. + The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.   22 Table of Contents   SIGNATURES   Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     MOLECULIN BIOTECH, INC.       Date: November 13, 2023 By: /s/ Walter V. Klemp     Walter V. Klemp,     Chief Executive Officer and Chairman (Principal Executive Officer)       Date: November 13, 2023 By: /s/ Jonathan P. Foster     Jonathan P. Foster,     Executive Vice President & Chief Financial Officer (Principal Financial and Accounting Officer)     23